Lantheus Holdings Inc represents a set of core values and embodies a corporate philosophy centered on excellence, innovation, and patient care. As a leading developer and manufacturer of diagnostic imaging agents, the company aims to improve medical outcomes and enhance patient well-being. Lantheus Holdings Inc prioritizes strong relationships with healthcare professionals and stakeholders to deliver safe, effective, and high-quality imaging solutions. With a commitment to advancing precision medicine, the company constantly strives to meet evolving medical needs by fostering collaboration, embracing technological advancements, and adhering to the highest ethical standards within the healthcare industry.

Lantheus Holdings Inc is primarily present in the United States.

Lantheus Holdings Inc has achieved several significant milestones in its history. The company has successfully developed and commercialized innovative diagnostic imaging agents used in various medical fields. Lantheus Holdings Inc also expanded its global presence by establishing collaborations and partnerships with leading pharmaceutical companies. This has allowed the company to enhance its product portfolio and increase its market reach. Furthermore, Lantheus Holdings Inc has demonstrated consistent financial growth and stability, positioning itself as a trusted and reliable player in the healthcare industry. With its continuous focus on research and development, Lantheus Holdings Inc remains committed to advancing diagnostic imaging solutions for the benefit of patients and healthcare providers worldwide.

Lantheus Holdings Inc. is a leading medical imaging company founded in 1956. Headquartered in North Billerica, Massachusetts, Lantheus specializes in developing, manufacturing, and commercializing innovative diagnostic imaging agents and products. The company has a rich history of advancements in medical imaging technologies, including the creation of contrast agents for use with ultrasound and nuclear imaging procedures. Lantheus has built a solid reputation for delivering high-quality imaging solutions that help healthcare professionals make accurate diagnoses and improve patient care. With a strong commitment to research and development, Lantheus continues to drive advancements in medical imaging and remains a trusted name in the industry.

The main competitors of Lantheus Holdings Inc in the market include General Electric Healthcare, Bracco Imaging, and Bayer AG.

Lantheus Holdings Inc is primarily active in the healthcare and pharmaceutical industries.

The business model of Lantheus Holdings Inc revolves around the development, manufacturing, and commercialization of diagnostic medical imaging agents and products. Lantheus specializes in providing innovative diagnostic solutions to support healthcare professionals in accurately identifying and treating various medical conditions. The company leverages its expertise in medical imaging technology to create and distribute a diverse portfolio of contrast agents, including ultrasound and radiopharmaceutical imaging agents. Lantheus focuses on improving patient outcomes by delivering high-quality diagnostic imaging tools that aid in the detection and management of diseases.

Lantheus Holdings KGV ir 11,40.

Lantheus Holdings KUV ir 3,44.

AlleAktien kvalitātes vērtējums Lantheus Holdings ir 7/10.

gaidāmā Lantheus Holdings apgrozījums ir 1,63 miljardi USD.

gaidāmā Lantheus Holdings peļņa ir 493,09 milj. USD.

Lantheus Holdings Inc. is a biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions. It was founded in 1956 and is headquartered in North Billerica, Massachusetts. Lantheus operates subsidiaries and branches worldwide to serve the global market. Lantheus operates in three business segments: Imaging, Radiopharmaceuticals, and Medical Isotopes. In the Imaging segment, the company offers diagnostic products for various applications. This includes contrast agents for several medical imaging technologies used to diagnose various diseases such as cardiovascular diseases, prostate cancer, and thyroid cancer. Imaging solutions offered include contrast agents for echocardiography and magnetic resonance imaging, as well as ultrasound and computer-aided detection solutions. In the Radiopharmaceuticals segment, Lantheus is one of the leading companies in the field. Radiopharmaceuticals are used for the fast and accurate diagnosis of various metabolic disorders and types of cancer. The products are developed in collaboration with partners and marketed under the TechneLite brand. TechneLite products are radiopharmaceuticals for myocardial perfusion scintigraphy, a commonly used method for diagnosing heart diseases. Lantheus also develops and produces Medical Isotopes for use in medical applications such as PET scans. The company offers a range of Medical Isotopes, including molybdenum-99. Lantheus' business model puts customers at the center. The company strives to offer innovative and high-quality products and services tailored to the needs of customers. Lantheus pursues an Agile Development strategy, which focuses on quickly implementing new product ideas. As a marketing strategy, Lantheus relies on differentiated competitive advantages. This means the company serves niches where there are few or no competitors. The use of radiopharmaceutical substances offers strong growth potential. However, competition in the market is relatively high. Overall, Lantheus is a leading company in the field of medical imaging and radiopharmaceuticals. With its innovative products and services, as well as agile development, the company aims to provide customers with the highest quality and optimal solutions tailored to their specific needs.

Lantheus Holdings izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Lantheus Holdings vai uzņēmums nedod dividendes.

Lantheus Holdings ISIN ir US5165441032.

Lantheus Holdings WKN ir A117UE.

Lantheus Holdings simbols ir LNTH.

Pēdējo 12 mēnešu laikā Lantheus Holdings maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Lantheus Holdings plāno maksāt dividendes 0 USD apmērā.

Lantheus Holdings pašreizējā dividendu rentabilitāte ir .

Lantheus Holdings maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Lantheus Holdings pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Lantheus Holdings tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Lantheus Holdings apmērā 0 USD, kas tika izmaksāta 26.02.2025., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 26.02.2025..

Pēdējās dividendes izmaksa notika 26.02.2025..

Gadā 2024, Lantheus Holdings izmaksāja 0 USD dividendes.

Lantheus Holdings dividendes tiek izmaksātas USD.